Ruthigen nets $16.5mm via IPO of units
Executive Summary
Seven months after filing, Ruthigen Inc. (hypochlorous acid-based therapeutics for infections) netted $16.5mm through the initial public offering of 2.8mm units (including the overallotment) at $7.25. A unit consists of one common share; one two-year Series A warrant exercisable for one share at $7.25; and one five-year Series B warrant to purchase one share at $9.0625. In October 2013 the company announced plans to offer 1.5mm common shares between $12-14, and five months later said it intended to sell 2.2mm shares between $7.25-9.25 each.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice